Aluminum in Vaccines: Not Linked to Disorders
New Study Excludes Link Between Childhood Vaccine Aluminum and Chronic Health Conditions
Table of Contents
A comprehensive study published in The Lancet Infectious Diseases has provided robust evidence, excluding a link between cumulative aluminum exposure from childhood vaccines and a wide range of chronic health conditions, including autoimmune disorders, allergies, and neurodevelopmental issues. The research, which tracked over 150,000 children, reinforces the established safety profile of aluminum-containing vaccines, a cornerstone of public health for nearly a century.
Rigorous Analysis of Vaccine Exposure and Health Outcomes
The study, funded by the Danish Government, meticulously examined the health records of children born in Denmark between 1990 and 2013. Researchers focused on the cumulative aluminum exposure from vaccines administered during infancy,specifically the DTaP-IPV-Hib (pentavalent) vaccine and the pneumococcal conjugate vaccine. These vaccines, crucial for protecting against serious diseases like diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b, are administered in three doses during the first year of life. Since 2007, the Danish vaccination programme also includes an aluminum-adsorbed pneumococcal conjugate vaccine, also given in three doses in the first year.
The research team then followed the health trajectories of these children from age 2 up to age 5, or until December 31, 2020. During this period, they monitored for diagnoses of 50 diffrent chronic conditions. These included autoimmune diseases such as juvenile arthritis, atopic or allergic conditions like asthma and atopic dermatitis, and neurodevelopmental disorders, notably autism spectrum disorders.
The median cumulative aluminum exposure for the entire cohort was 3 mg, with individual exposures ranging from 0 mg to 4.5 mg. A small subset of 15,237 children received no aluminum-containing vaccines during the study period, serving as a critical control group.
Excluding Risk “With Grate Certainty”
The analysis revealed no discernible relationship between the cumulative amount of aluminum exposure from vaccines and any of the 50 chronic conditions investigated. For autoimmune disorders, the adjusted hazard ratio (aHR) per 1 mg of aluminum exposure was 0.98 (95% CI, 0.94-1.02). similarly, for atopic or allergic outcomes, the aHR was 0.99 (95% CI, 0.98-1.01), and for neurodevelopmental outcomes, it was 0.93 (95% CI, 0.90-0.97).
The most frequently diagnosed conditions within the study cohort were asthma, with 28,346 cases, and atopic dermatitis, with 22,978 cases. The researchers found no association between cumulative aluminum exposure from vaccines and the incidence of either of these common conditions.
“For some of the key outcomes that people are most interested in, like asthma and autism spectrum disorders, the results are quite clear, and we can exclude meaningful increases in risk with great certainty,” stated lead researcher Anders Hviid.He further noted that while some associations, such as with autism spectrum disorders, showed a slightly decreased risk, the confidence intervals were close to one, indicating these were not interpreted as relevant protective effects.
Reassuring Findings Across secondary Analyses
To further strengthen the findings, secondary analyses were conducted. These included extending the follow-up period to 8 years of age, excluding all children who had no exposure to aluminum-containing vaccines, and restricting the analysis to complete cases. All these adjusted analyses consistently found no association between the chronic conditions and exposure to aluminum in vaccines.
Dr. James Campbell, a professor in the Department of Pediatrics at the University of Maryland School of Medicine and vice chair of the American Academy of Pediatrics’ committee on infectious diseases, commented on the study’s significance. “With all these adjustments, they still didn’t find any differential in the effect. I think all of that is very reassuring,” he said.
Dr. campbell emphasized that this paper “adds to the long history of studies” on the safety of aluminum-containing vaccines. “Aluminum salts have been around for almost 100 years as an adjuvant; we have such a long history of using them,both in the United States and across the world,” he told Medscape.”The aggregate of the data are that aluminum salt adjuvants are safe to be given to children.”
The study authors reported no relevant financial relationships. Dr. Campbell reports serving as a site primary investigator for vaccine trials with institutional funding from Pfizer,Moderna,GSK,Sanofi,and Merck.